Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.
Journal: Clinical and translational science
Published: January 16, 2025
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 18, 2023
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: July 14, 2022
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Journal: Science translational medicine
Published: December 23, 2021
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 01, 2021
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
Journal: medRxiv : the preprint server for health sciences
Published: June 23, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Journal: The Journal of antimicrobial chemotherapy
Published: June 15, 2021
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
Journal: Trials
Published: April 28, 2021
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Journal: Antimicrobial agents and chemotherapy
Published: March 02, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026